Cancer cell genomic DNA at programmed oncogenic or cancer-relevant loci (Oncogenic DNA loci)

Cancer cell genomic DNA at programmed oncogenic or cancer-relevant loci refers to specific sequences within the genome of a malignant cell that drive tumor growth, survival, and metastasis [1]. These loci often harbor mutations, amplifications, or translocations in proto-oncogenes such as KRAS, MYC, or BRAF, or deletions in tumor suppressor genes like TP53 [2]. Targeting these specific sites allows for therapeutic interventions aimed at correcting or disabling the genetic drivers of the disease [3]. Modern approaches include gene editing technologies like CRISPR-Cas9, which can be programmed to create double-strand breaks at precise oncogenic sequences, leading to gene knockout or repair [1]. Traditional chemotherapeutic agents also interact with genomic DNA through alkylation or intercalation, though they lack the sequence specificity of programmable nucleases [4]. By focusing on these critical genomic regions, researchers aim to achieve high therapeutic precision while minimizing damage to healthy cells [3]. [1] Nature Reviews Cancer (2019) 19:225-240. [2] NIH National Cancer Institute, 'The Cancer Genome Atlas Program'. [3] PubMed PMC6335130. [4] StatPearls, 'Alkylating Agents'.

Other names

Oncogenic DNACancer-associated genomic lociTumor-specific DNA sequencesMutated genomic DNACancer genome

Programmable nucleases (e.g., CRISPR-Cas9) induce site-specific double-strand breaks (DSBs) at oncogenic loci to disrupt gene function or facilitate precise sequence correction [1]. Conventional cytotoxic agents like alkylators (e.g., cisplatin) form covalent DNA adducts, while intercalators (e.g., doxorubicin) wedge between base pairs, both of which interfere with DNA replication and transcription, ultimately triggering apoptosis [4, 5]. PARP inhibitors like olaparib exploit deficiencies in DNA repair at these loci to induce synthetic lethality [2]. [5] PubChem, 'Cisplatin'.